UPDATE: Morgan Stanley Maintains Equal-Weight On Regeneron, Raises Target To $387 As Firm Notes 'Eylea outperformed and cost control continued in the JV improving profitability. Pipeline updates from NSCLC, bispecifics and C5 were encouraging'
Benzinga_Newsdesk